Combined local blood-brain barrier opening and systemic methotrexate for the treatment of brain tumors

Journal of Cerebral Blood Flow and Metabolism

Volumn 35, Issue 6, 2015, Pages 967-976

  Cooper, Itzik ^a,b,c   Last, David ^a   Guez, David ^a   Sharabi, Shirley ^a,d   Elhaik Goldman, Shirin ^a   Lubitz, Irit ^a   Daniels, Dianne ^a,d   Salomon, Sharona ^a   Tamar, Gregory ^a   Tamir, Tzur ^d   Mardor, Ronni ^a   Fridkin, Mati ^b   Shechter, Yoram ^b   Mardor, Yael ^a,d  

^a SHEBA MEDICAL CENTER   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c INTERDISCIPLINARY CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

blood brain barrier; brain cancer; convection; glioma; tight junctions

Indexed keywords

ETHYLAMINE; HUMAN SERUM ALBUMIN; METHOTREXATE; OCCLUDIN; ANTINEOPLASTIC ANTIMETABOLITE; SERUM ALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN TOXICITY; BRAIN TUMOR; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GLIOMA; IMMUNOCYTOCHEMISTRY; LEUKOCYTE MIGRATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCREENING; SYNTHESIS; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; BRAIN; BRAIN NEOPLASMS; CELL LINE; CHEMISTRY; DRUG EFFECTS; HUMAN; LEWIS RAT; PATHOLOGY; PIG; PROCEDURES; THERMODYNAMICS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CELL LINE; CONVECTION; DRUG DELIVERY SYSTEMS; ETHYLAMINES; GLIOMA; HUMANS; MALE; METHOTREXATE; RATS; RATS, INBRED LEW; SERUM ALBUMIN; SWINE;

EID: 84930177551     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.6     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
2. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012; 14: v1-49.
3. Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol 2010; 12: 520-527.
4. Dhanikula RS, Argaw A, Bouchard JF, Hildgen P. Methotrexate loaded polyethercopolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharm 2008; 5: 105-116.
5. Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud A, Sgouros G. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer 2004; 112: 713-721.
6. Pardridge WM, Triguero D, Buciak J, Yang J. Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector. J Pharmacol Exp Ther 1990; 255: 893-899.
7. Cooper I, Sasson K, Teichberg VI, Schnaider-Beeri M, Fridkin M, Shechter Y. Peptide derived from HIV-1 TAT protein destabilizes a monolayer of endothelial cells in an in vitro model of the blood-brain barrier and allows permeation of high molecular weight proteins. J Biol Chem 2012; 287: 44676-44683.
8. Bergmann P, Kacenelenbogen R, Vizet A. Plasma clearance, tissue distribution and catabolism of cationized albumins with increasing isoelectric points in the rat. Clin Sci (Lond) 1984; 67: 35-43.
9. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 2001; 46: 247-279.
10. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convectionenhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994; 91: 2076-2080.
11. Vogelbaum MA, Iannotti CA. Convection-enhanced delivery of therapeutic agents into the brain. Handb Clin Neurol 2012; 104: 355-362.
12. Mehta AI, Choi BD, Raghavan R, Brady M, Friedman AH, Bigner DD et al. Imaging of convection enhanced delivery of toxins in humans. Toxins (Basel) 2011; 3: 201-206.
13. Sampson JH, Akabani G, Friedman AH, Bigner D, Kunwar S, Berger MS et al. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus 2006; 20: E14.
14. Tanner PG, Holtmannspotter M, Tonn JC, Goldbrunner R. Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. Neurosurgery 2007; 61: E880-E882, discussion E882.
15. Saito R, Sonoda Y, Kumabe T, Nagamatsu K, Watanabe M, Tominaga T. Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride. J Neurosurg Pediatr 2011; 7: 522-526.
16. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004; 100: 472-479.
17. Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003; 49: 92-104.
18. Birlik B, Canda S, Ozer E. Tumour vascularity is of prognostic significance in adult, but not paediatric astrocytomas. Neuropathol Appl Neurobiol 2006; 32: 532-538.
19. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996; 77: 362-372.
20. Cooper I, Cohen-Kashi Malina K, Cagnotto A, Bazzoni G, Salmona M, Teichberg VI. Interactions of the prion peptide (PrP 106-126) with brain capillary endothelial cells: coordinated cell killing and remodeling of intercellular junctions. J Neurochem 2011; 116: 467-475.
21. Franke H, Galla H, Beuckmann CT. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the bloodbrain barrier in vitro. Brain Res Brain Res Protoc 2000; 5: 248-256.
22. Cohen-Kashi Malina K, Cooper I, Teichberg VI. Closing the gap between the invivo and in-vitro blood-brain barrier tightness. Brain Res 2009; 1284: 12-21.
23. Rutten MJ, Hoover RL, Karnovsky MJ. Electrical resistance and macromolecular permeability of brain endothelial monolayer cultures. Brain Res 1987; 425: 301-310.
24. Mardor Y, Rahav O, Zauberman Y, Lidar Z, Ocherashvilli A, Daniels D et al. Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res 2005; 65: 6858-6863.
25. Stevenson BR, Keon BH. The tight junction: morphology to molecules. Annu Rev Cell Dev Biol 1998; 14: 89-109.
26. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37: 13-25.
27. Lai CH, Kuo KH, Leo JM. Critical role of actin in modulating BBB permeability. Brain Res Brain Res Rev 2005; 50: 7-13.
28. Raza SM, Lang FF, Aggarwal BB, Fuller GN, Wildrick DM, Sawaya R. Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery 2002; 51: 2-12, discussion 12-3.
29. Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004; 84: 397-405.
30. Nieto-Sampedro M, Valle-Argos B, Gomez-Nicola D, Fernandez-Mayoralas A, Nieto-Diaz M. Inhibitors of glioma growth that reveal the tumour to the immune system. Clin Med Insights Oncol 2011; 5: 265-314.
31. Doolittle ND, Muldoon LL, Culp AY, Neuwelt EA. Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances. Adv Pharmacol 2014; 71: 203-243.
32. Zylber-Katz E, Gomori JM, Schwartz A, Lossos A, Bokstein F, Siegal T. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic bloodbrain barrier disruption in patients with brain lymphoma. Clin Pharmacol Ther 2000; 67: 631-641.
33. Goldman ID, Matherly LH. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates. NCI Monogr 1987; 5: 17-26.
34. Vandenbroucke E, Mehta D, Minshall R, Malik AB. Regulation of endothelial junctional permeability. Ann NY Acad Sci 2008; 1123: 134-145.
35. Hamm S, Dehouck B, Kraus J, Wolburg-Buchholz K, Wolburg H, Risau W et al. Astrocyte mediated modulation of blood-brain barrier permeability does not correlate with a loss of tight junction proteins from the cellular contacts. Cell Tissue Res 2004; 315: 157-166.
36. Dobrogowska DH, Vorbrodt AW. Immunogold localization of tight junctional proteins in normal and osmotically-Affected rat blood-brain barrier. J Mol Histol 2004; 35: 529-539.
37. Youakim A, Ahdieh M. Interferon-gamma decreases barrier function in T84 cells by reducing ZO-1 levels and disrupting apical actin. Am J Physiol 1999; 276: G1279-G1288.
38. D'Agnillo F, Williams MC, Moayeri M, Warfel JM. Anthrax lethal toxin downregulates claudin-5 expression in human endothelial tight junctions. PLoS One 2013; 8: e62576.
39. Hammond MD, Ambler WG, Ai Y, Sansing LH. alpha4 integrin is a regulator of leukocyte recruitment after experimental intracerebral hemorrhage. Stroke 2014; 45: 2485-2487.
40. Al Nimer F, Lindblom R, Strom M, Guerreiro-Cacais AO, Parsa R, Aeinehband S et al. Strain influences on inflammatory pathway activation, cell infiltration and complement cascade after traumatic brain injury in the rat. Brain Behav Immun 2013; 27: 109-122.